MARKET

RVMD

RVMD

REVOLUTION MEDICINES, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

30.72
+0.48
+1.59%
Closed 16:00 05/29 EDT
OPEN
30.26
PREV CLOSE
30.24
HIGH
31.76
LOW
29.63
VOLUME
237.37K
TURNOVER
--
52 WEEK HIGH
47.14
52 WEEK LOW
17.35
MARKET CAP
1.81B
P/E (TTM)
-23.9122
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RVMD stock price target is 48.33 with a high estimate of 55.00 and a low estimate of 40.00.

EPS

RVMD News

More
Why Blackstone Stock Looks Attractive
Also, Wall Street views on the shares of Exxon Mobil, Shopify, Revolution Medicines, and Heartland BancCorp
Barrons.com · 05/23 02:29
HC Wainwright & Co. Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $55
HC Wainwright & Co. analyst Robert Burns initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $55.
Benzinga · 05/21 11:18
Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
GlobeNewswire · 05/19 12:30
Revolution Medicines EPS misses by $0.41, misses on revenue
Revolution Medicines (NASDAQ:RVMD): Q1 GAAP EPS of -$0.74 misses by $0.41. Revenue of $11.55M (-12.3% Y/Y) misses by $1.83M. Press Release
seekingalpha · 05/15 01:34
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate Progress
Closed Initial Public Offering Raising Gross Proceeds of $273.7 Million Presented First Evidence of Clinical Activity of SHP2 Inhibitor (RMC-4630) Against KRAS Mutant Lung.
GlobeNewswire · 05/14 20:05
Stocks That Hit 52-Week Highs On Thursday
During Thursday's morning session, 55 companies made new 52-week highs.
Benzinga · 05/07 14:33
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models
GlobeNewswire · 04/29 13:05
Mirati Therapeutics down 6% as Kerrisdale shorts
Seeking Alpha - Article · 04/21 14:39

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About RVMD

Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.
More

Webull offers kinds of Revolution Medicines Inc stock information, including NASDAQ:RVMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVMD stock news, and many more online research tools to help you make informed decisions.